ABT-925 fumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574547

CAS#: 220519-07-3 (fumarate)

Description: ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.

Chemical Structure

img
ABT-925 fumarate
CAS# 220519-07-3 (fumarate)
Instruction

Theoretical Analysis

MedKoo Cat#: 574547
Name: ABT-925 fumarate
CAS#: 220519-07-3 (fumarate)
Chemical Formula: C24H31F3N6O5S
Exact Mass: 572.20
Molecular Weight: 572.600
Elemental Analysis: C, 50.34; H, 5.46; F, 9.95; N, 14.68; O, 13.97; S, 5.60

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1160247-85-7 (fumarate hydrate)   220519-06-2 (free base)   220519-07-3 (fumarate)   ABT-925 HCl    

Synonym: A 37203; A-37203; A37203; A 437203; A437203; A-437203; ABT 925; ABT925; ABT-925; BSF 201640; BSF201640; BSF-201640; DAT 201; DAT201; DAT-201; Lu 201640; Lu201640; Lu-201640;

IUPAC/Chemical Name: 2-[[3-[4-[2-(1,1-Dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-4(1H)-pyrimidinone (2E)-2-Butenedioate

InChi Key: KQMGYGQUUXCWBL-WLHGVMLRSA-N

InChi Code: InChI=1S/C20H27F3N6OS.C4H4O4/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18;5-3(6)1-2-4(7)8/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30);1-2H,(H,5,6)(H,7,8)/b;2-1+

SMILES Code: O=C1N=C(SCCCN2CCN(C3=NC(C(C)(C)C)=NC(C(F)(F)F)=C3)CC2)NC=C1.O=C(O)/C=C/C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 572.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kehr J, Wang FH, Ichinose F, Yoshitake S, Farkas B, Kiss B, Adham N. Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders. Front Psychiatry. 2022 Jan 12;12:801641. doi: 10.3389/fpsyt.2021.801641. PMID: 35095615; PMCID: PMC8789685.


2: Pich EM, Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. Eur Neuropsychopharmacol. 2015 Sep;25(9):1437-47. doi: 10.1016/j.euroneuro.2015.07.012. Epub 2015 Jul 21. PMID: 26298833.


3: Bhathena A, Wang Y, Kraft JB, Idler KB, Abel SJ, Holley-Shanks RR, Robieson WZ, Spear B, Redden L, Katz DA. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. Transl Psychiatry. 2013 Apr 9;3(4):e245. doi: 10.1038/tp.2013.22. PMID: 23571810; PMCID: PMC3641409.


4: Gross G, Wicke K, Drescher KU. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. PMID: 23128852.


5: Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N 4th, Saltarelli MD. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol. 2011 Apr;31(2):221-5. doi: 10.1097/JCP.0b013e31820e4818. PMID: 21346607.


6: Wan K, Rieser M, El-Shourbagy T. Quantitative Determination of ABT-925 in Human Plasma by On-Line SPE and LC-MS/MS: Validation and Sample Analysis in Phase II Studies. Pharmaceutics. 2010 May 4;2(2):171-181. doi: 10.3390/pharmaceutics2020171. PMID: 27721349; PMCID: PMC3986714.


7: Day M, Bain E, Marek G, Saltarelli M, Fox GB. D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol. 2010 Apr;13(3):291-2. doi: 10.1017/S1461145710000180. Epub 2010 Mar 3. PMID: 20196920.


8: Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol. 2010 Apr;13(3):273-87. doi: 10.1017/S1461145709990642. Epub 2009 Sep 15. PMID: 19751545.